Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results - PubMed (original) (raw)

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

Sharon E Plon et al. Hum Mutat. 2008 Nov.

Abstract

Genetic testing of cancer susceptibility genes is now widely applied in clinical practice to predict risk of developing cancer. In general, sequence-based testing of germline DNA is used to determine whether an individual carries a change that is clearly likely to disrupt normal gene function. Genetic testing may detect changes that are clearly pathogenic, clearly neutral, or variants of unclear clinical significance. Such variants present a considerable challenge to the diagnostic laboratory and the receiving clinician in terms of interpretation and clear presentation of the implications of the result to the patient. There does not appear to be a consistent approach to interpreting and reporting the clinical significance of variants either among genes or among laboratories. The potential for confusion among clinicians and patients is considerable and misinterpretation may lead to inappropriate clinical consequences. In this article we review the current state of sequence-based genetic testing, describe other standardized reporting systems used in oncology, and propose a standardized classification system for application to sequence-based results for cancer predisposition genes. We suggest a system of five classes of variants based on the degree of likelihood of pathogenicity. Each class is associated with specific recommendations for clinical management of at-risk relatives that will depend on the syndrome. We propose that panels of experts on each cancer predisposition syndrome facilitate the classification scheme and designate appropriate surveillance and cancer management guidelines. The international adoption of a standardized reporting system should improve the clinical utility of sequence-based genetic tests to predict cancer risk.

(c) 2008 Wiley-Liss, Inc.

PubMed Disclaimer

Figures

Figure 1

Figure 1

The algorithm used for data combination during evaluation of possible carcinogens

Figure 2

Figure 2

The index case (arrowed) was referred to the genetics service following the diagnosis of a grade 3 breast cancer. Her mother died of a serous papillary ovarian carcinoma aged 48 years. Genetic testing revealed variant D3095E in the BRCA2 gene.

Similar articles

Cited by

References

    1. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Passini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, nton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008 - PMC - PubMed
    1. Balleyguier C, Ayadi S, Van NK, Vanel D, Dromain C, Sigal R. BIRADS classification in mammography. Eur J Radiol. 2007;61:192–194. - PubMed
    1. Barnetson RA, Cartwright N, van VA, Haq N, Drew K, Farrington S, Williams N, Warner J, Campbell H, Porteous ME, Dunlop MG. Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer. Hum Mutat. 2008;29:367–374. - PubMed
    1. Becker F, Nusko G, Welke J, Hahn EG, Mansmann U. Benefit-risk analysis of different risk-related surveillance schedules following colorectal polypectomy. Hepatogastroenterology. 2007;54:2249–2258. - PubMed
    1. Boerner S, Sneige N. Specimen adequacy and false-negative diagnosis rate in fine-needle aspirates of palpable breast masses. Cancer. 1998;84:344–348. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources